MRC2: A Protein Implicated in Cell Adhesion, Migration and Angiogenesis

Target Name: MRC2

NCBI ID: G9902

MRC2

MRC2: A Protein Implicated in Cell Adhesion, Migration and Angiogenesis

MRC2 (C-type lectin domain family 13 member E) is a protein that is expressed in various cell types of the human body, including macrophages, dendritic cells, and epithelial cells. It is a 21-kDa protein that consists of 215 amino acid residues. MRC2 is involved in various cellular processes, including cell adhesion, migration, and invasion.

MRC2 is a member of the C-type lectin domain family 13, which includes proteins that share similar structures and functions. These domains are characterized by the presence of a conserved core domain, which is composed of a helix and a parallel beta-sheet, as well as a variable region that is unique to each member of the family.

MRC2 is a cytoplasmic protein that is primarily located in the cytoplasm of cells. It is a monomer that consists of a single polypeptide chain that is composed of 215 amino acids. MRC2 has a calculated molecular mass of 21.3 kDa and a calculated pI of 7.9.

MRC2 is involved in various cellular processes, including cell adhesion, migration, and invasion. It is a critical regulator of cell-cell adhesion, as it helps to maintain the integrity of the intercellular junctions that mediate cell-cell communication. MRC2 is also involved in the regulation of cell migration and invasion, as it plays a role in the migration of cancer cells to new tumors and the invasion of normal tissues by these cells.

MRC2 has also been shown to be a potential drug target in various diseases. For example, MRC2 has been shown to be overexpressed in various types of cancer, including breast cancer, lung cancer, and colon cancer. It is also involved in the regulation of the angiogenesis, which is the process by which new blood vessels are formed in tumors. MRC2 has been shown to be involved in the regulation of angiogenesis by various signaling pathways, including the TGF-β pathway and the Wnt pathway.

MRC2 is also a potential biomarker for various diseases, including cancer. Its overexpression has been shown to be associated with the development and progression of various types of cancer. For example, MRC2 has been shown to be overexpressed in various types of cancer, including breast cancer, lung cancer, and colon cancer. This suggests that it may be a useful biomarker for these diseases, as it can be used as a target for therapeutic interventions.

In conclusion, MRC2 is a cytoplasmic protein that is involved in various cellular processes, including cell adhesion, migration, and invasion. It is a member of the C-type lectin domain family 13 and has a calculated molecular mass of 21.3 kDa. MRC2 has has been shown to be involved in the regulation of cell-cell adhesion, cell migration, and angiogenesis, and has been shown to be a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of MRC2 in these processes and to develop effective therapeutic interventions.

Protein Name: Mannose Receptor C Type 2

Functions: May play a role as endocytotic lectin receptor displaying calcium-dependent lectin activity. Internalizes glycosylated ligands from the extracellular space for release in an endosomal compartment via clathrin-mediated endocytosis. May be involved in plasminogen activation system controlling the extracellular level of PLAUR/PLAU, and thus may regulate protease activity at the cell surface. May contribute to cellular uptake, remodeling and degradation of extracellular collagen matrices. May play a role during cancer progression as well as in other chronic tissue destructive diseases acting on collagen turnover. May participate in remodeling of extracellular matrix cooperating with the matrix metalloproteinases (MMPs)

The "MRC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets